cyrilzakka/clinical-trials huggingface dataset:
Acupuncture for Functional Dyspepsia: a Functional Magnetic Resonance Imaging (fMRI) Study

He-Mu-point combination（ST36 and CV12） is one of the most commonly used acupoints combination with synergistic effect for functional dyspepsia(FD). The investigators design the trial to identify the efficacy and explore the central integrated mechanism of puncturing at He-Mu-point combination on FD with functional magnetic resonance imaging (fMRI).

105 participants with functional dyspepsia will be allocated into three groups: Low-He point group, Mu point group and He-Mu-point combination group.Every participant will receive 20 sessions of manual acupuncture treatment during 4 weeks. Clinical evaluations will be assessed three times, as measured after randomization, 10 and 20 sessions of treatment.The fMRI scans will be conducted twice, after randomization and treatment completion.

Eligibility Criteria:
Inclusion Criteria:

1. right handed，age between 18 and 45 years old, college degree or above;
2. match the Rome III criteria on FD;
3. no local organic disease by gastroscope examination;
4. before entering the study, without taking any prokinetic agents at least 15days and participating in other clinical study;
5. signing an informed consent in writing by the participant or the immediate family member.

Exclusion Criteria:

1. consciousness, cannot express subjective symptoms and psychiatric participants;
2. participants with advanced cancer or other serious wasting diseases, easy to be infected and bleeding;
3. complicating with severe cardiovascular, hepatic,nephritic,digestive, hematopoietic system diseases;
4. impregnate or lactation female;
5. severe depression and anxiety symptoms;
6. female with serious dysmenorrhea;
7. obvious headache, migraine, history of head injury.
Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Iodinated Activated Charcoal

The purpose of this study s to determine whether treatment with Iodinated Active Charcoal can improve lung function and physical capacity in patients with chronic obstructive lung disorders. The rational for the study is the observation that COPD patients have an increased tissue load of mercury interfering with the function by NeuroEpithelial Endocrine (NEE) cells in the respiratory tract. Mercury binding to these NEE cells leads to an increased smooth muscle tonus and a reduced response to bronchodilator treatment. Initial observational data have shown an improved lung function and improved functional capacity after treatment motivating a larger placebo controlled POC study


Eligibility Criteria:
Inclusion Criteria:

* Male and \>1 year post-menopausal, or surgically sterile female.
* 45-80 years old.
* Smokers and ex-smokers, at least 15 pack years.
* COPD according to GOLD II. FEV% \< 70 Post beta2-agonist FEV1 \>50 \< 80 % of predicted value
* CO diffusion capacity \< 75 %.
* Active symptomatic COPD with a COPD assessment test (CAT) score \>10.

Exclusion Criteria:

* Alpha-1 antitrypsin deficiency
* Iodine allergy
* Abnormal thyroid function
* Severely reduced kidney function (Cystatin C \> 1.5 mg/L.
* Exacerbation within 4 weeks prior to the study.
* Use of per oral steroids within 4 weeks prior to the study.
* Alcohol/drug abuse.
* Psychiatric disease.
* Severe cardio-vascular or other severe disease, according to the clinical investigator.
* Oxygen treatment.
* Participation in another ongoing clinical trial or participation in drug
Rib Removal and Pain in Partial Nephrectomy

In this study, the effect of rib removal on postoperative pain in kidney cancer patients undergoing retroperitoneal open partial nephrectomy with flank incision was investigated. For this purpose, VAS score surveys were prepared for patients who underwent partial nephrectomy surgery in the early and late postoperative periods.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged over 18 years who underwent open renal surgery due to kidney cancer were included in the study.

Exclusion Criteria:

* Patients with a preoperative (one day before surgery) VAS score greater than 0,
* Those with additional known diseases that could cause pain (herniated disc, urinary stone disease, inflammatory bowel diseases, other intra-abdominal pathologies),
* Intraoperative complications that could cause postoperative pain, metastasis, positive surgical margins or peri-renal invasion,
* Those who underwent laparoscopic surgery or those who converted to open surgery after laparoscopic surgery,
* Patients that regularly used painkillers for other reasons,
* Patients whose ribs other than the 11th rib were removed were excluded from the study.
UNCOVER - a Non-interventional Study to Investigate Undiagnosed Severe Asthma

UNCOVER is a non-interventional study to investigate the prevalence of difficult-to-treat and severe Asthma eligible for treatment with biologics in a cohort of patients with suspected, so far undiagnosed severe Asthma which were previously treated by General practitioners and Office-based pulmonologists.


Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older at inclusion
* written informed consent
* currently diagnosed with Asthma fulfilling at least one of the criteria of potential severe Asthma
* willing and able to complete the study questionnaire miniAQLQ

Exclusion Criteria:

* biological Treatment for Asthma during the past 12 months
* participation in a clinical Trial within the last 3 months
* patients who are not able to read or write, who do not understand the nature of the study or the ICF or who are dependent from the investigator
INFUSE Morphine Study

Double-blind study comparing the pharmacokinetics, safety and tolerability of morphine administered subcutaneously (SC) with and without human recombinant hyaluronidase (HYLENEX) and intravenously conducted in patients in a hospice care setting or through a palliative care medicine setting. In this within-patient controlled study, each eligible study patient receives a single injection by each of the three methods of morphine administration, sequentially on three consecutive days, according to the order specified by a randomization schedule.

Each of the three injections consists of 5 mg of morphine (1.0 mL of 5 mg/mL solution). The HYLENEX injection will be 1 mL of 150 units. Although the IV administration will not be blinded, the two SC injections will be double-blinded, using the same volume of normal saline (0.9% sodium chloride) placebo (1.0 mL) as HYLENEX.


Eligibility Criteria:
Inclusion Criteria:

1. Males or females at least 18 years of age who are patients of San Diego Hospice \& Palliative Care or recruited through San Diego Hospice \& Palliative Care or the UCSD Center for Pain and Palliative Medicine.
2. During the treatment days of the study, on opioid therapy other than morphine that is equivalent to ≥ 60 mg oral morphine per day and without unacceptable toxicity.
3. Vital signs (BP, HR, RR) within normal range.
4. Adequate venous access in both upper extremities.
5. A negative pregnancy test (if female of child-bearing potential) within 7 days prior to first injection.
6. Life expectancy ≥ ten days.
7. Decision-making capacity.
8. Signed, written IRB-approved informed consent. -

Exclusion Criteria:

1. Known hypersensitivity or history of any toxicity to morphine.
2. Morphine within the 4 days prior to the first study medication injection or anticipated to be receiving morphine during any of the treatment days in this study.
3. Any contraindication to morphine.
4. Known hypersensitivity to naloxone.
5. Known allergy to hyaluronidase or any other ingredient in the formulation of HYLENEX.
6. Known allergy to bee or vespid venom.
7. Contraindication to IV heparin lock or known hypersensitivity to heparin.
8. Edema, infection, or any other lower extremity or pelvic disorder that might affect subcutaneous absorption from the thigh.
9. Hemoglobin \< 10 g/dL.
10. Presence of any other medical condition that would present an unacceptable safety risk to the patient.
11. Participation in a study of any investigational drug or device within 30 days of enrollment in this study.
Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization

The purpose of this study is to determine whether Yili Lactoferrin ShuHua Milk are effective in reducing the occurrence of flu symptoms.


Eligibility Criteria:
Inclusion Criteria:

* Age 6 to 12 years, catch cold for 4 to 6 times in last year;
* Age 35 to 45 years, catch cold for 4 to 6 times in recent 3 month;
* Age 60 to 75 years, catch cold for 4 to 6 times in last year;
* BMI 18.5to 29.9kg/m2;
* Able to understand the nature and purpose of the study including potential risks and side effects

Exclusion Criteria:

* Recent (within 6 months of screening) been vaccinated influenza vaccine, or recent (within 15 days of screening) been vaccinated ther vaccines;
* Suffering from rhinitis chronic, laryngitis, labored breathing that similar to flu symptoms. Such as chronic allergic rhinitis, asthma, COPD;
* Long-term use of any prescription or OTC medication that inhibit or prevent flu symptoms, including but not limited to, antihistamine, pectoral, high doses of vitamin C;
* Recent use (within 3 months of screening) of any prescription or OTC medication that significantly affects immune response, such as antibiotic;
* Known allergies to dairy and any substance in the study product;
* History of alcohol, drug, or medication abuse
* Pregnant or breastfeeding women
* Recent daily use (within 3 months of screening) of any probiotics, clabber or yogurt;
* Any comorbidity that could, in the opinion of the investigator, preclude the subject's ability to successfully and safely complete the study or that may confound study outcomes
Methods of Placental Delivery and the Amount of Blood Loss During Cesarean Section

To compare between the effect of controlled cord traction and manual removal of the placenta on blood loss among women undergoing caesarean sections

Cesarean section (CS) is one of the most commonly performed major abdominal operations in women worldwide and its rate is increasing dramatically every year.

Some of the reported short-term morbidities include hemorrhage, postoperative fever and endometritis. The method of delivering the placenta is one procedure that may contribute to an increase or decrease in the morbidity of CS.

On an average 0.5-1 liter of blood is lost during CS, many variable techniques have been tried to reduce this blood loss. Such techniques include finger splitting versus scissor cutting of incision, in situ stitching verses exteriorization and stitching of uterus , and finally spontaneous or manual removal of the placenta.

Two common methods used to deliver the placenta at CS are cord traction and manual removal.

Manual removal of the placenta which the obstetrician introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the infant and controlled cord traction in which the obstetrician do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery.

Opinions differ about the best for placental delivery technique at CS. Some trials showed a reduced risk of blood loss with controlled cord traction (3) and others showed that manual removal of placenta at CS do not increase perioperative blood loss.

Authors concluded that manual delivery of the placenta was significantly associated with greater operative blood loss and greater decrease in postoperative hemoglobin levels and postpartum maternal infectious morbidity but with shorter operative time compared with spontaneous placental separation .

In addition, it is known that the blood loss at CS delivery is difficult to estimate, and numerous different methods including serial change in hematocrit (Hct), hemoglobin (Hb) level, visual estimation and the gravimetric method are described.

A low, but significant, correlation was found between visually estimated blood loss and perioperative hemoglobin change in women delivering by CS. However, hemoglobin , hematocrit levels and visual estimation are the most commonly used technique for estimating blood loss at delivery.

Eligibility Criteria:
Inclusion Criteria:

- All informed and consented women undergoing elective or emergency CS will be legible for enrollment into the study

Exclusion Criteria:

* Multiple gestation.
* Pregnancy below 34 weeks.
* Severe maternal anemia.
* Severe pre-eclampsia
* Prolonged labor.
* Prolonged rupture of the membranes with fever.
* Placental abruption.
* Placenta previa.
* Placenta accreta.
* Clotting disorders.
* Current or previous history of a significant disease including heart disease, liver, renal disorders.
Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults

This study will evaluate the efficacy of a multifactorial approach associated with orlistat (Xenical) in weight loss maintenance during 4 years. The effect of orlistat in combination with diet, physical activity, and/or cognitive behavioral therapy will be monitored.


Eligibility Criteria:
Inclusion Criteria:

* Body mass index (BMI) greater than or equal to (\>/=) 30 kilograms per meter-squared (kg/m\^2), or BMI \>/= 28 kg/m\^2 with risk factors of diabetes, hypertension, or hyperlipidemia, before weight loss
* Documented weight loss \>/= 10% of initial body weight obtained with diet, with or without psychological therapy or orlistat

Exclusion Criteria:

* Pregnant or lactating females
* History or presence of significant medical disorders
* Active gastrointestinal disorders such as peptic ulcer disease or malabsorption syndromes
* Pancreatic disease: pancreatic enzyme deficiency, history or current presence of pancreatitis
* Clinically significant abnormal clinical chemistry or hematology results
* Excessive alcohol intake
* Smoking cessation within the previous 6 months
* History or presence of cancer
* Administration of medicines known to alter body weight
* History or presence of cancer
The Effectiveness of a Mobile Interactive Supervised Therapy (MIST) Intervention for Improving Adherence to HIV Medication

A total of 40 HIV infected patients will be randomly assigned into intervention or control group. Participants in the intervention group will use an smart phone application for two months. Participants will receive reminder notifications and use the app to take and send videos of themselves taking the pill(s), uploaded videos will be centrally reviewed by a study nurse . Control group participants will receive standard care. Antiretroviral Therapy adherence will be measured by self-report, pill count, and smart bottle as well as the App. Participants' perceptions of app using experience will be recorded via face to face interview.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 21
* HIV infection diagnosis confirmed by western blot
* Taking a once daily regimen of HIV medications
* Able to take pills orally
* Willing and able to give informed consent

Exclusion Criteria:

* Inability to operate a smart phone
* Active Tuberculosis infection requiring treatment during study (due to additional challenge posed to adherence that may confound the assessment of HIV adherence)
* Substance use
* Visual or hearing impairment
* Cognitive impairment
SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with Osimertinib


Eligibility Criteria:
Inclusion Criteria:

1. Patients must have biopsy proven metastatic NSCLC (Stage IV).
2. Patients receiving first-line Osimertinib for EGFR mutant-positive for 3 months and achieved stable disease or partial response.
3. Age 18 to 75 years old.
4. Patients must have measurable disease at baseline.
5. The amount of metastatic focus \<5.
6. ECOG score 0-2 7 Adequate normal organ and marrow function for TKI treatment and radiotherapy.

8. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R) 9. Patients must provide written informed consent to participate in the study.

Exclusion Criteria:

1. Patients who previously received radiotherapy to the primary site.
2. Patient can't tolerate radiotherapy or targeted therapy;
3. Pregnant or nursing women
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy

This purpose of the study is to investigate the bronchodilating effects of 3 different dosages of formoterol given in combination with budesonide as Symbicort pMDI.

A Phase 2, randomized, blinded, 5-period cross-over, placebo and active controlled, multicenter, dose-finding study comparing single doses of formoterol 2.25 µg, 4.5 µg, and 9 µg delivered via Symbicort pMDI and Foradil® 12 µg evaluating the relative bronchodilating effects and safety in children.

Eligibility Criteria:
Inclusion Criteria:

* Has a documented clinical diagnosis of asthma for at least 6 months prior to Visit 1
* Has a FEV1 measured at least 6 hours after the last dose of inhaled, short-acting β2-agonist (SABA) and at least 48 hours after the last dose of inhaled long-acting β2-agonist of =60% and =85% of predicted normal.
* Demonstrated reversibility of FEV1 of =15% from pre short acting beta agonist level within 15 to 30 minutes after administration of a standard dose of short acting beta agonist

Exclusion Criteria:

* Has been hospitalized for \>24 hours at least once or required emergency treatment or urgent care visit more than once for an asthma-related condition during the 6 months prior to Visit 1
* Has required treatment with systemic corticosteroids (eg, oral, parenteral, or rectal) for any reason within the 12 weeks prior to Visit 1.
Effects of Lomitapide on Carotid and Aortic Atherosclerosis

Study to assess changes in carotid and aortic atherosclerosis in patients being treated with lomitapide.

This is a multi-center long-term open-label non-comparative study to assess changes in carotid and aortic atherosclerosis in patients being treated with lomitapide. Patients from countries in the EU, the US and Canada who are being treated with lomitapide and are enrolled in The Lomitapide Observational Worldwide Evaluation Registry (LOWER), will be invited by the LOWER enrolling physician to participate in this substudy.

Eligibility Criteria:
Inclusion Criteria:

• Adult patients (age ≥18 years) who are enrolled in LOWER

Exclusion Criteria:

* Patients with a prior history of carotid angioplasty, carotid stenting, or carotid atherectomy
* Patients with a contraindication to MRI examination (i.e., brain aneurysm, implanted neural stimulator, implanted cardiac pacemaker, pacemaker wires or defibrillator, prosthetic heart valves, cochlear implant, ocular foreign body, or other implanted body)
* Patients who have undergone a coronary stenting procedure in the preceding three weeks prior to enrollment
* Patients prone to claustrophobia or known anxiety disorders that will interfere with the ability to acquire quality MRI scans
* Patients with an implanted insulin pump
* Patients with metal shrapnel or bullet wounds
* Patients with a body mass index (BMI) \> 40 kg/m2 (since it may be difficult to position comfortably with the MRI scanner)
* Patients who work with metal lathes (unless an orbit x-ray performed prior to the enrollment MRI scan has been done to rule out metal fragments in the eye)
1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT

Parallel, Multi-Center, Double-masked, Active controlled, three arm study comparing the IOP lowering efficacy and safety over 12 months of morning or evening instillations of Travoprost/Brinzolamide vs. Cosopt dosed in the morning and evening in patients with open-angle glaucoma or ocular hypertension.


Eligibility Criteria:
Inclusion Criteria:

* IOP at screening visit \<18mmHg in at least one eye Mean IOP in same eye (at both eligibility 1 \&2 visits)

  * 24 and ≤ 36 mmHg at 9:00
  * 21 and ≤ 36 mmHg at 11:00 and 16:00

Exclusion Criteria:

* Severe central visual field loss Angle Shaffer grade \< 2 C/D ratio \> 0.8 (horizontal or vertical measurement)
Famotidine Versus Placebo in Emergency Pediatric Surgery As a Risk to Postoperative Nausea and Vomiting

The aim of this study is to evaluate the difference of the gastric volume by quantitative measurements of gastric antrum preoperatively and postoperatively by using 5mg famotidine versus placebo as a risk factor of PONV.

Gastric ultrasound examinations will be performed preoperatively and postoperatively on patients undergoing emergency surgery in pediatric. Gastric cross-sectional area (CSA) will be measured, in order to estimate the gastric volume. The data that will be obtained will be used to evaluate a difference of the gastric volume between the two groups preoperatively and postoperatively and the possible relationship between the gastric volume difference and postoperative adverse event (PONV).

Eligibility Criteria:
Inclusion Criteria:

* Pediatrics patients aging between 2-13 years .
* pediatrics undergo urgent surgery (i.e., surgery that cannot be postponed for more than 48 h since clinical onset).
* PatientPediatrics come in trauma

Exclusion Criteria:

* PatientPediatrics severly shocked .
* PatientPediatrics with diffusely distended abdomen as this will obstacle gastric ultrasound .
* PatientPediatrics with history of hypersenstivity to famotidine .
* PatientPediatrics with hepatic or renal impairments